Background & Summary
====================

Rotaviruses (RV) belong to the *Reoviridae* family, and have a linear segmented double-stranded RNA genome composed of 11 segments coding for 12 viral proteins. RV is a major cause of severe gastroenteritis among very young children in developing countries, and is a major cause of mortality in children under 5 years old, causing up to 20% of all childhood deaths in countries with high diarrheal disease burden with \>90% of these deaths occurring in Africa and Asia. Initial RV infections usually occur by 9 months of age, and 80% occur before 1-year of age^[@b1]^. Serogroup A RV are the leading causative agent of childhood (\<5 years) severe gastroenteritis worldwide, accounting for approximately 3.4% of child deaths annually^[@b6]^. The WHO has recommended, since 2009, that rotavirus vaccines be included in all national vaccination programs^[@b7]^.

There are two RV vaccines in use. Rotarix is a live vaccine containing the attenuated monovalent G1, P^[@b8]^ human rotavirus strain. RotaTeq is a live-attenuated bovine-human reassortant rotavirus vaccine containing the most common rotavirus antigens seen in humans (G1, G2, G3, G4, and P). Both vaccines are efficacious as has been demonstrated in clinical trials, i.e., 90--100% effective in preventing severe gastroenteritis, and clinical trial data have shown both vaccines to have acceptable safety profiles. Both vaccines are orally administered in multiple doses to mimic natural sequential rotavirus infections in an effort to promote the development of homotypic and heterotypic protective immunity against relevant group A rotavirus^[@b8]^. Current efforts to disseminate these vaccines to economically distressed areas are hindered largely by bioproduction costs.

Mammalian cells such as the Vero cell line have proven to be a safe production platform for developing human vaccines^[@b7],[@b9]^. Unfortunately, currently available Vero vaccine cell lines have relatively low yields compared to other vaccine production platforms. In an effort to rectify low-yield issues, as part of this study, we have identified host virus-resistant genes in a monkey kidney cell line, MA104 cells. The MA104 cells are highly susceptible to RV. Using small interfering RNA (siRNA) human library screening, a subset of genes in MA104 cells were identified that considerably increased RV replication when knocked down. The primary siRNA screen in the MA104 cells was achieved by reverse-transfecting the cells with pooled ON-TARGETplus siRNAs (SMARTpools) (4 siRNA targeting each gene) with the siRNA library targeting protein-coding host genes. Cytotoxic siRNAs as well as those which negatively affected cell viability were identified and excluded. Two days post-transfection cells were infected with activated simian rotavirus (RV3). Twenty-four hours post-infection cells were fixed and virus quantified by fluorescence focus assay (IF ELISA) ([Fig. 1](#f1){ref-type="fig"}). Seventy hits increased viral replication ≥3 s.d.s. (z-score≥3.0) above non-targeting control ([Fig. 2](#f2){ref-type="fig"}). A WHO-derived Vero cell line, previously utilized in the production of vaccine cell lines, was used to re-screen hits in an effort to eliminate false-positives. The top 20 hits that recapitulated the primary MA104 cell line screen were subjected to deconvolution studies. In this case, individual siRNAs included in SMARTpools were tested individually to determine if they induced the phenotype observed of the pool, i.e., increased RV replication and changes in viral antigen production. As part of this validation screen, Vero cells were reverse-transfected with individual siRNAs (4 siRNAs per gene) in triplicate per a transfection protocol optimized for Vero cells. Forty-eight hours post-transfection cells were infected with the RV3 rotavirus strain. Viral replication was evaluated via IF ELISA ([Fig. 3](#f3){ref-type="fig"}). Ten hits showed an increased in RV3 replication of 1.75 fold or higher (NEU2, NAT9, COQ9, SVOPL, NDUFA9, COX9, LRGUK, WDR62, RAD51AP1 and CDK6) ([Table 1](#t1){ref-type="table"}). Messenger RNA knockdown (KD) under infection conditions was confirmed with qRT-PCR ([Fig. 4](#f4){ref-type="fig"}). Gene knockout (KO) Vero cell lines were generated with CRISPR-cas 9 plasmids. KO was confirmed via Sanger sequencing (data not shown). RV3, CDC-9 and Rotarix replication was evaluated by qPCR in these engineered cell lines. In the NEU2-KO Vero cells generated, Rotarix infection had the highest increase of viral transcript at \~18-fold increase, followed by the RV3 (reference strain) at \~10-fold, and CDC-9 at \~7.5-fold increase ([Fig. 5](#f5){ref-type="fig"}).

Methods
=======

Cell culture and viral stocks
-----------------------------

The rhesus monkey epithelial cell line (MA104) was chosen to perform the primary RNAi screen because these cells support rotavirus replication and are easily transfected. The effects of gene silencing on rotavirus replication in MA104 cells can be detected 16--24 h (h) post-infection (pi). Hits produced from this primary screen were validated in the African green monkey kidney cell line (Vero), which is used for the production of the licensed polio virus vaccine. Vero cells are an approved cell line for vaccine production, and the cell line was received from the Centers of Disease Control and Prevention (CDC, Atlanta) who obtained it from the Serum Institute of India (SI). Both cell lines were cultivated under conditions of 37 °C, 5% CO~2~ in Dulbecco's modified Eagle's medium (DMEM; Hyclone, GE Healthcare) supplemented with 10% heat inactivated fetal bovine serum (FBS; Hyclone, GE Healthcare) and 1% penicillin-streptomycin. A master cell stock was created with low passage cells for both cell types. Briefly, master cell stocks were generated for low-passaged Vero and MA104 cells, where cells were cultured 6 days prior to screening experiments. The primary RNAi screens were done in MA104 cells by seeding MA104 cells in 96-well plates at a cell density of 10,000 cells per well. Rescreening and validation screening was accomplished in the same 96-well plate format with Vero cells seeded at a cell density of 8,000 cells per well. Passage numbers were consistent throughout the screen and validation steps to reduce variability.

The primary RNAi screening was done using a single lot of a attenuated RV vaccine strain, RV3-BB (RV3)^[@b10]^. RV3 was initially prepared as a vaccine at a low titer (6.5×10^5^ FFU ml^−1^) in Melbourne, Australia by the Carl Kirkwood lab. High titer RV3 virus was produced in the WHO-approved Vero cell line under Good Manufacturing Practice (GMP) conditions at Meridian Life Sciences, Memphis. RV3 is currently propagated in monkey kidney cell cultures (Vero cells) and subjected to downstream purifications. We expect that other RV strains may share the same pathways for virus replication as the currently licensed RV3 vaccine strain. For this reason, other RV strains were examined as part of the validation experiments to determine whether silencing the top hits determined as part of the primary screening with RV3 also lead to increased viral replication in vaccine cell lines with a variety of RV strains. Subsequent validation steps were completed in Vero cells with the RV3-BB strain, RotaTeq (G1P7, G2P7, G3P7, G4P7, G6P1A), Rotarix (89-12/G1P) and CDC-9 rotavirus strains.

SiRNA transfection
------------------

An ON-TARGETplus small interfering RNA (SMARTpools) library (GE Healthcare) was utilized to screen protein-coding host genes in MA104 cells as part of the primary screen. Primate-specific siRNA libraries are not currently readily available, therefore we used a human library of siRNAs to target the entire genome. According to the Chimpanzee Sequencing and Analysis Consortium, primates share 96% DNA sequence identity with humans. Therefore, utilizing siRNAs targeting human genes should target monkey sequences with strong complementarity^[@b11]^. SMARTpools utilize sense strand inaction and seed-region modifications that reduce off-target effects while maintaining high selectivity and effectiveness. As part of the primary RNAi screen, each gene was targeted with pooled SMARTpools. Each pool contained four siRNAs targeting a different seed region of the target gene's mRNA. Briefly, in a 96-well plate format, MA104 cells were reverse transfected with 50 nM siRNA pools using 0.4% DharmaFECT 4 transfection reagent (0.4 ul well^−1^) (GE Healthcare). SMARTpools were pre-incubated with DharmaFECT 4 reagent in serum-free DMEM media at room temperature for 20 min to allow for complex formation. MA104 cells (1.4×10^4^ cells well^−1^) in DMEM supplemented with 10% heat inactivated fetal bovine serum (FBS) were added to each well. Transfection plates were cultured at 37 °C, 5% CO~2~. Forty-eight hours post-transfection media was removed and cells infected with rotavirus strain as previously stated. Subsequent deconvolution studies utilized the same method of transfection except each siRNA was delivered individually. Each transfection experiment includes a non-targeting control siRNA (NTC; GE Healthcare). This siRNA targets no known mRNA sequence and should have no effect on mRNA. A siRNA targeting RV3 was used as a positive control, siTOX (GE Healthcare) served as a transfection control. All siRNAs were transfected to a final concentration of 50 nM.

Elimination of false-positive hits
----------------------------------

Genome-wide RNAi screen data shows that the percentage of false-positive hits produced following primary screening can be high, in part due to the working with high numbers of assays including transfection, infection, fixation, variations from plate to plate, and delays in sequential plate reads. In the current study, the primary siRNA screening was performed in a MA104 cell line, which supports rotavirus replication. However, our endpoint for gene editing was performed in a Vero cell line that we used to support current vaccine development. To help aid in removal of potential false-positive hits in the primary screening, we performed a secondary screen of this collection of hits in a Vero cell line. The pooled siRNAs were transfected into Vero cells in a 96-well cell culture plate in triplicate. Rotavirus replication was examined by ELISA assay and the data was normalized to non-targeting control (NTC) as described. Seventy-six genes were selected for secondary screening in the Vero cell line. The majority of genes selected for re-screening studies were selected based upon z-score analysis. Initially, genes that exhibited a z-score≥3.0 were included. This list was further modified to include genes that were predicted to be relevant during virus replication following a brief study that assessed genes with a z-score ranging from 2.9--3.0 by conducting basic pathway analysis and a literature search. Genes were excluded during this process based upon their predicted relevance to virus replication. The finalized list of 76 genes is outlined in [Fig. 2](#f2){ref-type="fig"}.

Deconvolution studies
---------------------

Twenty hits that repeated in the primary screen results following screening in Vero cells were chosen based upon the increased virus replication with a relative value \>1.4 (normalized to NTC) and subjected to deconvolution studies ([Table 2](#t2){ref-type="table"} (available online only)). As part of these studies the siRNAs included in each SMARTpool were individually tested to determine whether individual siRNAs gave rise to changes in viral antigen production determined by IF ELISA. For each gene, 4 individual siRNAs from SMARTpools were evaluated. Forty-eight hours post-transfection, the cells were infected with RV3 at a MOI 0.2. Forty-eight hours post-infection, cells were fixed for the IF ELISA assay as discussed in methods section. A siRNA targeting RV3 was used as a positive control, siTOX served as a transfection control and a non-target siRNA served as a negative control. Gene targets were considered confirmed if two individual siRNAs enhanced RV3 replication during the deconvolution screening with a relative value \>1.4 (normalized to NTC). To confirm siRNA efficacy, mRNA levels for each gene target were evaluated following transfection and subsequent infection by qPCR. All data represents the mean of triplicates±s.e.m., and normalized to non-targeting control.

Toxicity and cellular viability screening
-----------------------------------------

The top 76 hits were tested for effects on cellular viability and toxicity by CellTiter96 Non-Radioactive Cell Proliferation Assay Kit and ToxiLight bioassay (Lonza, Walkersville, MD) ([Fig. 6](#f6){ref-type="fig"}). SiRNAs were reverse transfected into MA104 cells (10,000 per well) to a final concentration of 50 nM. Seventy-two hours post-transfection, 20 μl per well of CellTiter 96 Non-Radioactive Cell Proliferation Assay (G4000, Promega Inc) was added to the siRNA transfected cells and incubated at 37 °C in cell culture incubator for 1 h. Following incubation, 100 μl of the solubilization solution/stop mix was added to each well. Absorbance was evaluated at a wavelength of 570 nm with a plate spectrophotometer (Tecan). Absorbance values were normalized to non-targeting siRNA control absorbance values.

qRT-PCR
-------

Gene silencing by siRNA transfection in Vero cells was confirmed for the top ten genes. Cells were transfected in triplicate with individual siRNAs as previously described. Forty-eight hours post-transfection, cells were harvested for RNA isolation using RNeasy Mini Kit (Qiagen) following manufacturer instructions. qRT-PCR was performed in triplicate to measure mRNA levels of targeted genes using 1 ug RNA (SYBR Green RT Kit; ThermoFisher). The cycle threshold (CT) values were normalized to the house keeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) or 18s ribosomal RNA. Values are presented as the mean of the triplicates±s.e.m.

RV infection
------------

For both primary and deconvolution experiments, MA104 cells or Vero cells were infected with an activated simian rotavirus (RV3) 48 h post-transfection. Briefly, RV stocks were activated by adding 10 ug ml^−1^ of L-(tosylamido-2-phenyl) ethyl chloromethyl ketone (TPCK) treated trypsin (Worthington; Lakewood, NJ) and heating for 1 h in a 37 °C water bath. Following activation, rotavirus was diluted to a multiplicity of infection (MOI) of 0.2 in media containing trypsin at a 1 ug ml^−1^ concentration. One hundred microliters of diluted RV was added to each well after first washing plates ×2 with HBSS to remove all traces of FBS. Infected plates were incubated for 4 h at 37 °C, 5% CO~2~. Subsequent to incubation, 100 ul of DMEM containing 10% FBS was added to the plates on top of existing infection and incubated for a total of 24 h under the same conditions. Twenty-four hours post-infection supernatants were harvested and cells fixed with acetone:PBS for 20--30 min and stored at 4 °C until ready to perform the IF ELISA. KO cell lines were examined for virus replication using two RV vaccine strains CDC-9 and Rotarix (GSK P5) (CDC) following the same protocol.

IF ELISA
--------

Fixed plates were washed ×2 with PBS for rehydration then blocked with 0.05% phosphate buffered saline with Tween 20 (PBST) containing 1% BSA for 1 h at room temperature on a rotator. The primary polyclonal rabbit anti-Rotavirus antibody (Rab A-SA11; Melbourne, Australia) 1:1,000 in blocking solution was added at 50 ul well^−1^ for 1 h at room temperature. The primary antibody was removed and plates were washed ×4 with 0.05% PBST followed by the addition 50 ul well^−1^ of a fluorescently labeled secondary antibody (goat/Anti-rabbit Alexa 488) at 1:1,000 dilution for 1 h at room temperature. Secondary antibody was removed by washing ×2 with PBST and ×2 with PBS. Plates were read with the Beckman Coulter Paradigm spectrophotometer capable of detecting fluorescence. Plates were read individually using a 450 nm wavelength filter at an exposure time of 1 min. Values were normalized to non-targeting control wells in the same plate.

CRISPR-Cas9
-----------

Following the re-screening and deconvolution studies, KOs of the top 10 hits were generated in Vero cells using CRISPR-Cas9. These 10 genes were chosen based upon assay results i.e., they resulted in the highest fold-change compared to NTC (enhanced virus replication versus non-targeting control). CRISPRs (GE) were used to generate 5 of the 10 knockouts. Utilization of the CRISPRs requires the co-transfection of a GFP-Cas9, the CRISPR RNA (crRNA) and the trans-activating RNA (tracrRNA). Briefly, the crRNA associates with Cas9. This complex locates and binds the target DNA via base pairing interaction with the tracrRNA. The clones generated using this system did not produce targeted gene cleavage in Vero cells, CRISPRs (Sigma) were utilized in further gene editing experiments. The CRISPRs (Sigma) system utilizes a single plasmid that expresses both green fluorescent protein (GFP) and guide RNA (gRNA). Four guide strands were evaluated per gene target. Currently, we have successfully generated a KO cell line for the NEU2 gene in Vero cells. Other KO was attempted, and generation of other KO cell lines is on-going. The CRISPR (Sigma) sequences utilized in these experiments are presented in [Table 3](#t3){ref-type="table"}.

Gene editing was applied to generate KO vaccine cell lines (Sigma) using CRISPR-Cas selected genes was done in Vero cells maintained in Dulbecco's modified Earle's medium (DMEM, Invitrogen) supplemented with 10% fetal bovine serum. Lipofectamine LTX Reagent (Life Technologies) was utilized to transfect CRISPR plasmids into the Vero cells in 12-well culture plates, with a ratio of DNA/Lipofectamine at 1.0 ug/3.0 ul. Briefly, both 1.0 ug of CRISPR plasmid DNA and Lipofectamine were diluted into 100 ul of OPTI-MEM separately (Gibco Life Technologies; Carlsbad, CA). Diluted CRISPR plasmids were then mixed with transfection reagents and incubated at room temperature for 30 min. The cells were washed using ×1 PBS before the CRISPR/Lipofectamine mixture was added to the plate. Positive cells are sorted by flow cytometry into 96-well cell culture plates, with one cell/per well. Afterwards, the cell clones were grown in 12 well plates until confluence, and then divided into two plates: one plate was harvested for isolation of genomic DNA and then subjected to in-house Sanger sequencing; the second plate was frozen down at −80C until knockouts were validated by the sequencing data.

Data analysis
-------------

For all experiments a non-targeting control siRNA (GE; D-001810-0X) was used as a negative control. The raw data was normalized to the non-targeting control results for the respective plate and then converted to a standard Z-score. For the initial screen hits were normalized and scored based on wells showing ≥3 s.d. above or below a non-targeting control. siRNAs that elicited an enhancement of viral replication\>3 s.d.s. (z-score≥3.0) as compared to non-targeting control were considered top hits. These 76 genes were subjected to re-screening in Vero cells using SMARTpools.

Data Records
============

Data record 1
-------------

In this primary RNAi screen using small interfering RNA (siRNA), a library of siRNAs targeting human genes (GE Healthcare Dharmacon, \# G-005005-01) was screened and a subset of genes in MA104 cells were identified that when silenced dramatically increased the ability of rotavirus replication. Also, included within this dataset, are the genes that when silenced dramatically decreased the ability of rotavirus replication. Sub-libraries included within this library: GPCR (G-103605-01), Phosphatase (G-103705-01), Ion Channel (G-103805-01), Drug targets (G-104655-025), Protease (G-105105-01), Ubiquitin (GU-105615-01, G-105625-01 and G-105635-01 for Ubiquitin Subset 1, 2 and 3 respectively), Protein Kinase (G-103505-01), and Genome (G-105005-025). Included within this dataset is the raw ELISA data and calculated z-scores for each gene hit. Anti-RV hits with a z-score greater than 1 are considered to be plausible antiviral host genes. The siRNA primary screen data presented is stored at PubChem (Data Citation 1).

Data record 2
-------------

The top anti-RV hits from the primary screening assays were re-screened in a WHO-derived Vero vaccine cell line, which was the cell substrate to be used for enhanced vaccine cell line develop, to eliminate false-positive hits. In this case, individual siRNAs included in SMARTpools were tested to determine if they induced the phenotype observed of the pool, i.e., increased RV replication and changes in viral antigen production. Included within this dataset is the raw ELISA data for and calculated fold change for the host virus-resistant genes identified. Included within this dataset the host virus-resistant genes identified. This deconvolution validation dataset is stored at PubChem (Data Citation 2).

Technical Validation
====================

Optimization of transfection in Vero cell line
----------------------------------------------

To establish a highly efficient siRNA transfection protocol for high-throughput screening (HTS), the effectiveness of four DharmaFECT transfection reagents (DF1--4, Dharmacon) were tested with MA104 cells. From this collection, DF4 was identified to be the most effective reagent for introducing siRNAs into the cell line for primary screening ([Fig. 7](#f7){ref-type="fig"}). A result showing optimal DF4 transfection conditions is shown in [Fig. 8](#f8){ref-type="fig"}. Using a siRNA targeting the GAPDH gene, \>80% silencing was achieved with 0.4% DF4 and a siRNA concentration of 50 nM. These conditions are consistent with previously published data^[@b12]^. Under these conditions, cell toxicity was not observed by either microscopy examination or MTT assay. Transfection optimization for the Vero cell line (used for validation studies) was previously performed during the polio cell line engineering program^[@b12]^. Pilot studies were completed prior to screening to develop an assay with low variation and strong signal to noise ratio. Effective concentrations of siRNAs were determined by titration. Responses to negative and positive control siRNAs were evaluated and optimized to determine reference values and the s.d. for the z-score calculation. Z-scores were subsequently used to evaluate and determine hits.

Transfection controls
---------------------

All experiments were performed in at least two independent replicates. Each replicate included duplicates for each siRNA targeting a specific mRNA transcript for the gene of interest, and quadruplicates of a positive control siRNA targeting Rotavirus, a negative non-targeting control siRNA and a transfection control siRNA (siTOX). A high-quality RNAi screen requires a clear distinction between positive and negative controls. A control siRNA that targets Rotavirus directly was utilized to monitor the silencing effects on rotavirus replication (NSP-842: AGTTGAACGTGACGACAATT). A non-targeting siRNA (siNTC) (GE Healthcare Dharmacon: Cat. \# D-001810-0X) was used as a negative control. These controls were clearly distinguished from each other in all experiments. A mock control (no siRNA) was used as background normalization. The effectiveness of these controls is outline in [Fig. 7](#f7){ref-type="fig"}. In an effort to evaluate screening efficiency, we used siTOX (GE Healthcare Dharmacon TOX Transfection Control, Cat. \# D0015000120) to visually monitor the transfection efficiency. Successful transfection with siTOX results in cell death by apoptosis.

Toxicity and cellular viability screening
-----------------------------------------

All siRNAs were tested for effects on cellular viability and toxicity by CellTiter96 Non-Radioactive Cell Proliferation Assay Kit and ToxiLight bioassay (Lonza, Walkersville, MD) following manufacturer's instructions. Cellular toxicity was evaluated 48 h post-transfection. Data was normalized to siTOX control (100% cytotoxicity). siRNAs which resulted in \>20% toxicity were excluded as is standard operating procedure.

Data normalization and statistical analysis
-------------------------------------------

In the current study, we used Z-score analysis according to previously established methods^[@b13]^. A Z′-factor was utilized in the current screen (3\>Z′\>0.5: Excellent assay; 0.5\>Z′\>3: acceptable) to evaluate its quality. The majority of our screen fell into a Z′ factor (0.5\<Z′\<3.0) that reflects a high-quality primary screen. The primary screen data was normalized to the whole 96-well plate to set the mean (μ) of the data to zero and the s.d. to 1. The raw ELISA absorbance data values were normalized. The mean of the replicates where calculated and standardized using Z-score analysis. The mean values of the experimental siRNA treated wells were compared to the mean of the negative control treated wells. Z-score was calculated by determining the difference between the normalized score and the mean of the plate. This value was then divided by the s.d. of the plate. Positive hits from the primary screen are scored by Z-score≥3 s.d. Statistical analysis was completed by using a one-way ANOVA with Turkey's multiple comparisons at 95% confidence level. All data are presented as mean±s.e. *P*-values \<0.05 were considered statistically significant.
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![Experimental workflow.\
This study included a tiered siRNA screening approach coupled with CRISPR-generated knockout Vero cell lines to evaluate host genes and their implication during RV infection. The primary siRNA screen was performed with pooled OTP-siRNA in MA104 cell line using the simian rotavirus strain RV3. Top hits were selected by a z-score analysis and subjected to deconvoluted validation siRNA screens in Vero cells with the rotavirus strains RV3-BB, Rotarix, CDC-9. Resulting hits were evaluated in CRISPR generated Vero cell lines with CDC-9 and Rotarix (GSK P5) strains.](sdata201721-f1){#f1}

![Primary genome-wide siRNA screen in MA104 cell line.\
Eighteen thousand two hundred forty genes were targeted with siRNAs. Forty-eight hours post-transfection cells were infected with the strain RV3. Twenty-four hours post-infection the cells were fixed and IF ELISA was completed. KD of 76 genes resulted in an enhancement of viral replication ≥3 s.d.s. (z-score≥3.0) as compared to non-targeting control. All samples were completed in triplicate (*n*=3). These 76 genes were validated by deconvolution of pooled siRNAs.](sdata201721-f2){#f2}

![Deconvolution and validation of hits in Vero cell line.\
Presented is the relative fold-change of RV3 replication in siRNA transfected Vero cells compared to non-targeting control cells. The data is shown as mean values±s.d. To efficiently remove false positive from the siRNA primary screen in MA104, we re-screened these 76 hits using SMARTpool siRNAs targeting these genes in Vero cells. siRNAs were transfected into Vero cells following the methods optimized for Vero cells. Forty-eight hours post-siRNA transfection, cells were infected with RV3 using an MOI=0.2, and cells were harvested for RV3 IF ELISA 48 h.p.i. All samples were completed in triplicate (*n*=3). a.u., arbitrary units.](sdata201721-f3){#f3}

![Validation of gene silencing by siRNA transfection in Vero cell line using qPCR.\
For the top 10 hits selected to perform gene editing the siRNA silencing was confirmed in Vero cells using SMART pool siRNAs. MRNA levels of each gene were measured 48 h post-siRNA transfection by qPCR. Each qPCR reaction utilized 1 ug RNA as part of the reverse transcription reaction. Each gene was evaluated in triplicate and average values normalized to 18s rRNA. Values are presented as fold-change compared to non-targeting control (NTC). All samples were completed in triplicate (*n*=3). Values represent the mean of the triplicates±s.e.m.](sdata201721-f4){#f4}

![RV replication in NEU2-KO Vero cells.\
Using the CRISPR-Cas system a functinal NUE2 gene was edited and the RV3, CDC-9 and Rotarix rotavirus strains were evaluated. QPCR was performed in triplicate and the value was normalized to 18s RNA and compared to wild type Vero cell control (wt ctrl). All samples were completed in triplicate (*n*=3). The value presented here represents the mean of the triplicates±s.e.m.](sdata201721-f5){#f5}

![Cell viability assay.\
siRNAs were reverse-transfected into MA104 cells (10,000 per well) to a final concentration of 50 nM. Seventy-two hours post-transfection, 20 μl per well of CellTiter 96 Non-Radioactive Cell Proliferation Assay (G4000, Promega Inc) was added to the siRNA transfected cells and incubated at 37 °C in cell culture incubator for 1 h. Following incubation, 100 μl of the Solubilization Solution/Stop Mix was added to each well. Absorbance was evaluated at a wavelength of 570 nm with a plate spectrophotometer (Tecan).](sdata201721-f6){#f6}

![DharmaFECT 4 was the most effective transfection reagent for introducing siRNAs into MA104 cells.\
Prior to screening, DharmaFECT 1--4 were evaluated for their efficiency in delivering siRNAs to MA104 cells. A positive control siRNA targeting RV was transfected into MA104 cells using either 0.4 ul of DhamrmaFECT 1, 2, 3 or 4 following the protocol (ref). GAPDH expression was measured using QPCR assay. Results are presented as GAPDH expression versus non-targeting control.](sdata201721-f7){#f7}

![Transfection optimization.\
MA104 cells were transfected with DF4 and 50 nM GAPDH siRNA and allowed to incubate for 48 h. Following incubation cells were harvested to assess GAPDH silencing by qPCR. Shown is fold change in GAPDH mRNA following transfection with anti-GAPDH siRNA relative to control with no transfection reagent. DF4 at 0.4% concentration showed the highest mRNA reduction with the lowest toxicity as compared to DF1, DF2 and DF3.](sdata201721-f8){#f8}

###### Top 10 gene hits in Vero cells following deconvolution and subsequent validation.

  **Gene ID**   **Official Gene Name**                                           **Entrez Number**   **SMARTpool Catalog Number**
  ------------- --------------------------------------------------------------- ------------------- ------------------------------
  NEU2          Neuraminidase 2 (Cytosolic sialidase)                                  4,759               L-012058-02-0005
  NAT9          N-acetyltransferase 9 (Putative)                                      26,151               L-017635-02-0005
  COQ9          Coenzyme Q9                                                           57,017               L-022565-02-0005
  SVOPL         Synaptic vesicle glycoprotein 2 (SV2) related protein homolog        1,36,306              L-007346-01-0005
  NDUFA9        NADH:ubiquinone oxidoreductase subunit A9                              4,704               L-016044-01-0005
  COX20         Cytochrome c oxidase assembly factor                                 1,16,228              L-021429-01-0005
  LRGUK         Leucine-rich repeats and guanylate kinase containing domain          1,36,332              L-015997-01-0005
  WDR62         WD repeat domain 62                                                  2,84,403              L-015997-01-0005
  RAD51AP1      RAD51 recombinase associated protein 1                                10,635               L-017166-00-0005
  CDK6          Cyclin-dependent kinase 6                                              1,021               L-003240-00-0005

###### The top 76 hits were re-screened in a Vero vaccine cell line utilizing SMARTpools.

  **Gene Target**    **Entrez ID**   **Deconvoluted siRNA**   **Catalog number**   **Fold changes (versus NTC)**
  ----------------- --------------- ------------------------ -------------------- -------------------------------
  None                                        NTC                D-001810-0X                     1
  NEU2                   4,759              siRNA 1              J-012058-17                   1.196
  NEU2                   4,759              sIRNA 2              J-012058-18                   1.465
  NEU2                   4,759              siRNA 3              J-012058-19                   1.353
  NEU2                   4,759              siRNA 4              J-012058-20                   1.606
  NAT9                  26,151              siRNA 1              J-017635-13                   0.823
  NAT9                  26,151              sIRNA 2              J-017635-14                   1.241
  NAT9                  26,151              siRNA 3              J-017635-15                   1.484
  NAT9                  26,151              siRNA 4              J-017635-16                   1.442
  SVOPL                1,36,306             siRNA 1              J-007346-13                   0.777
  SVOPL                1,36,306             sIRNA 2              J-007346-14                   1.48
  SVOPL                1,36,306             siRNA 3              J-007346-15                   1.632
  SVOPL                1,36,306             siRNA 4              J-007346-16                   1.044
  COQ9                  57,017              siRNA 1              J-022565-18                   0.948
  COQ9                  57,017              sIRNA 2              J-022565-19                   1.531
  COQ9                  57,017              siRNA 3              J-022565-20                   1.477
  COQ9                  57,017              siRNA 4              J-022565-21                   1.26
  NDUFA9                 4,704              siRNA 1              J-016044-09                   1.085
  NDUFA9                 4,704              sIRNA 2              J-016044-10                   1.648
  NDUFA9                 4,704              siRNA 3              J-016044-11                   1.641
  NDUFA9                 4,704              siRNA 4              J-016044-12                   1.233
  RAD51AP1              10,635              siRNA 1              J-017166-05                   1.094
  RAD51AP1              10,635              sIRNA 2              J-017166-06                   1.217
  RAD51AP1              10,635              siRNA 3              J-017166-07                   1.568
  RAD51AP1              10,635              siRNA 4              J-017166-08                   1.478
  COX20                1,16,228             siRNA 1              J-021429-09                   1.021
  COX20                1,16,228             sIRNA 2              J-021429-10                   1.478
  COX20                1,16,228             siRNA 3              J-021429-11                   1.602
  COX20                1,16,228             siRNA 4              J-021429-12                   0.937
  MAPK6                  5,597              siRNA 1              J-003594-11                   1.361
  MAPK6                  5,597              sIRNA 2              J-003594-12                   1.405
  MAPK6                  5,597              siRNA 3              J-003594-13                   1.378
  MAPK6                  5,597              siRNA 4              J-003594-14                   1.067
  WDR62                2,84,403             siRNA 1              J-031771-09                   1.361
  WDR62                2,84,403             sIRNA 2              J-031771-10                   1.485
  WDR62                2,84,403             siRNA 3              J-031771-11                   1.402
  WDR62                2,84,403             siRNA 4              J-031771-12                   1.622
  LRGUK                1,36,332             siRNA 1              J-015997-09                   1.101
  LRGUK                1,36,332             sIRNA 2              J-015997-10                   1.585
  LRGUK                1,36,332             siRNA 3              J-015997-11                   1.161
  LRGUK                1,36,332             siRNA 4              J-015997-12                   1.568
  CDK6                   1,021              siRNA 1              J-003240-10                   1.315
  CDK6                   1,021              siRNA 2              J-003240-11                   1.434
  CDK6                   1,021              siRNA 3              J-003240-12                   1.529
  CDK6                   1,021              siRNA 4              J-003240-13                   0.951
  KIAA1683              80,726              siRNA 1              J-031251-05                   1.158
  KIAA1683              80,726              siRNA 2              J-031251-06                   1.242
  KIAA1683              80,726              siRNA 3              J-031251-07                   1.24
  KIAA1683              80,726              siRNA 4              J-031251-08                   1.097
  CRISP3                10,321              siRNA 1              J-020092-09                   0.969
  CRISP3                10,321              siRNA 2              J-020092-10                   1.454
  CRISP3                10,321              siRNA 3              J-020092-11                   1.436
  CRISP3                10,321              siRNA 4              J-020092-12                   1.218
  GRPR                   2,925              siRNA 1              J-005624-05                   1.039
  GRPR                   2,925              siRNA 2              J-005624-06                   1.535
  GRPR                   2,925              siRNA 3              J-005624-07                   1.925
  GRPR                   2,925              siRNA 4              J-005624-08                   0.971
  DPH7                  92,715              siRNA 1              J-016561-09                   1.121
  DPH7                  92,715              siRNA 2              J-016561-10                   1.343
  DPH7                  92,715              siRNA 3              J-016561-11                   1.573
  DPH7                  92,715              siRNA 4              J-016561-12                   1.275
  GEMIN8                54,960              siRNA 1              J-020841-17                    1.1
  GEMIN8                54,960              siRNA 2              J-020841-18                   1.047
  GEMIN8                54,960              siRNA 3              J-020841-19                   1.501
  GEMIN8                54,960              siRNA 4              J-020841-20                   1.437
  KIAA1407              57,577              siRNA 1              J-014068-17                   1.154
  KIAA1407              57,577              siRNA 2              J-014068-18                   1.292
  KIAA1407              57,577              siRNA 3              J-014068-19                   1.424
  KIAA1407              57,577              siRNA 4              J-014068-20                   1.089
  RFXAP                  5,994              siRNA 1              J-011104-05                   1.005
  RFXAP                  5,994              siRNA 2              J-011104-06                   1.514
  RFXAP                  5,994              siRNA 3              J-011104-07                   1.532
  RFXAP                  5,994              siRNA 4              J-011104-08                   1.669
  SMARCA4                6,597              siRNA 1              J-010431-05                   1.493
  SMARCA4                6,597              siRNA 2              J-010431-06                   1.51
  SMARCA4                6,597              siRNA 3              J-010431-07                   1.462
  SMARCA4                6,597              siRNA 4              J-010431-08                   1.698
  CFAP58               1,59,686             siRNA 1              J-026312-17                   1.452
  CFAP58               1,59,686             siRNA 2              J-026312-18                    1.4
  CFAP58               1,59,686             siRNA 3              J-026312-19                   1.366
  CFAP58               1,59,686             siRNA 4              J-026312-20                   1.558

###### Knockouts of the top 10 hits identified by the primary and validation RNAi screens were generated in Vero cells using CRISPR-Cas9.

  **Gene symbol**    **Gene ID**   **RefSeq ID**   **Species**   **Target exon**         **Order format**             **Target site**
  ----------------- ------------- --------------- ------------- ----------------- ------------------------------- ------------------------
  NEU2                  4,759        NM_005383        Human             1          Plasmid(U6-gRNA/CMV-Cas9-GFP)   AGGAGAGCGTGTTCCAGTCGGG
  NEU2                  4,759        NM_005383        Human             1          Plasmid(U6-gRNA/CMV-Cas9-GFP)   TGTTCCGCGAAGGCCAGCAGGG
  NEU2                  4,759        NM_005383        Human             1          Plasmid(U6-gRNA/CMV-Cas9-GFP)   GCTGGCCTTCGCGGAACAGCGG
  NEU2                  4,759        NM_005383        Human             1          Plasmid(U6-gRNA/CMV-Cas9-GFP)   AGCTGATTGTCCTGCGCAGAGG
  NAT9                 26,151        NM_015654        Human             2          Plasmid(U6-gRNA/CMV-Cas9-GFP)   CTCCGAGGTGTAGGGTACAAGG
  NAT9                 26,151        NM_015654        Human             3          Plasmid(U6-gRNA/CMV-Cas9-GFP)   CTCTGATTTCATCCACTCGTGG
  NAT9                 26,151        NM_015654        Human             4          Plasmid(U6-gRNA/CMV-Cas9-GFP)   TCTTCGGTGGCGCCTGGCTGGG
  NAT9                 26,151        NM_015654        Human             4          Plasmid(U6-gRNA/CMV-Cas9-GFP)   AGCTCTCTTCGGTGGCGCCTGG
  SVOPL               1,36,306     NM_001139456       Human             1          Plasmid(U6-gRNA/CMV-Cas9-GFP)   CGGCGGTATCTGGTGCGCTTGG
  SVOPL               1,36,306     NM_001139456       Human             1          Plasmid(U6-gRNA/CMV-Cas9-GFP)   GGTATCTGGTGCGCTTGGCCGG
  SVOPL               1,36,306     NM_001139456       Human             2          Plasmid(U6-gRNA/CMV-Cas9-GFP)   ACGCGGCACCAGGGCTTGTCGG
  SVOPL               1,36,306     NM_001139456       Human             2          Plasmid(U6-gRNA/CMV-Cas9-GFP)   AAACTCAAGGGCTGCCGTCAGG
  COQ9                 57,017        NM_020312        Human             1          Plasmid(U6-gRNA/CMV-Cas9-GFP)   GCTCAATTTCCGAAGGCTGAGG
  COQ9                 57,017        NM_020312        Human             1          Plasmid(U6-gRNA/CMV-Cas9-GFP)   GCCTTCGGAAATTGAGCCTGGG
  COQ9                 57,017        NM_020312        Human             2          Plasmid(U6-gRNA/CMV-Cas9-GFP)   CTTCCACGGTGAACGTCTTTGG
  COQ9                 57,017        NM_020312        Human             3          Plasmid(U6-gRNA/CMV-Cas9-GFP)   CAGTGGAGACTATCGGCTTCGG
  NDUFA9                4,704        NM_005002        Human             4          Plasmid(U6-gRNA/CMV-Cas9-GFP)   GCTGTGTTGTACTACTCGTCGG
  NDUFA9                4,704        NM_005002        Human             9          Plasmid(U6-gRNA/CMV-Cas9-GFP)   CGGTACCTCCTTTTCCACCTGG
  NDUFA9                4,704        NM_005002        Human             9          Plasmid(U6-gRNA/CMV-Cas9-GFP)   CGATAGGCAAAAAGCGGCAAGG
  NDUFA9                4,704        NM_005002        Human            11          Plasmid(U6-gRNA/CMV-Cas9-GFP)   GCGTCATCGCACTTACCGCTGG
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